KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Non-cash Items: 2012-2024

Historic Non-cash Items for Rigel Pharmaceuticals (RIGL) over the last 13 years, with Dec 2024 value amounting to $10.6 million.

  • Rigel Pharmaceuticals' Non-cash Items rose 44.17% to $17.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.3 million, marking a year-over-year increase of 44.17%. This contributed to the annual value of $10.6 million for FY2024, which is negligibly% changed negligibly from last year.
  • Latest data reveals that Rigel Pharmaceuticals reported Non-cash Items of $10.6 million as of FY2024, which was down 0.00% from $10.6 million recorded in FY2023.
  • In the past 5 years, Rigel Pharmaceuticals' Non-cash Items registered a high of $17.8 million during FY2020, and its lowest value of $1.6 million during FY2022.
  • For the 3-year period, Rigel Pharmaceuticals' Non-cash Items averaged around $7.6 million, with its median value being $10.6 million (2024).
  • Its Non-cash Items has fluctuated over the past 5 years, first tumbled by 97.80% in 2020, then spiked by 560.44% in 2023.
  • Rigel Pharmaceuticals' Non-cash Items (Yearly) stood at $17.8 million in 2020, then plummeted by 61.74% to $6.8 million in 2021, then tumbled by 76.44% to $1.6 million in 2022, then surged by 560.44% to $10.6 million in 2023, then remained steady at $10.6 million in 2024.